| Title | Author | Journal | Date |
|---|---|---|---|
| Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial | Atreya et al | The Lancet Gastroenterology and Hepatology | October 2020 |
| The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis View PDF |
Schmitt et al | Journal of Crohn’s and Colitis | October 2019 |
| Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis View PDF |
Atreya et al | Digestive and Liver Disease | June 2018 |
| Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis View PDF |
Atreya et al | Journal of Crohn’s and Colitis | November 2016 |
| Treatment of ulcerative colitis patients by local application of the Toll like Receptor-9 agonist DIMS0150 View PDF |
Löfberg et al | Gastrointestinal & Digestive System | December 2014 |
| Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B4 receptors. View PDF |
Admyre et al | Immunology | July 2014 |
| Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients View PDF |
Kuznetsov et al | BMC Gastroenterology | April 2014 |
| Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity View PDF |
Musch et al | Inflammatory Bowel Diseases | May 2012 |
| Inflammatory bowel disease classification through multigene analysis: fact or fiction? View PDF |
Petra von Stein | Expert Review of Molecular Diagnostics | February 2009 |
| Neither Hide Nor Hair: The Difficulty of Identifying Useful Disease Biomarkers View PDF |
Editorial | Gastroenterology | April 2008 |
| Multigene Analysis Can Discriminate Between Ulcerative Colitis, Crohn’s Disease, and Irritable Bowel Syndrome View PDF |
Von Stein et al | Gastroenterology | February 2008 |
| The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis View PDF |
Kuznetsov et al | Oncogene | February 2005 |
-
SVE
-
ENG
